Cytosorbents Corporation
CTSO
$0.59
$0.000.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.65% | -1.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.65% | -1.37% | |||
| Cost of Revenue | -13.80% | 0.57% | |||
| Gross Profit | 2.07% | -2.17% | |||
| SG&A Expenses | 14.29% | -8.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.37% | -8.20% | |||
| Operating Income | -52.18% | 26.36% | |||
| Income Before Tax | -53.93% | -283.41% | |||
| Income Tax Expenses | 100.00% | -- | |||
| Earnings from Continuing Operations | -73.41% | -262.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -73.41% | -262.81% | |||
| EBIT | -52.18% | 26.36% | |||
| EBITDA | -60.66% | 28.42% | |||
| EPS Basic | -73.27% | -262.38% | |||
| Normalized Basic EPS | -36.31% | -273.20% | |||
| EPS Diluted | -73.27% | -268.33% | |||
| Normalized Diluted EPS | -36.31% | -285.64% | |||
| Average Basic Shares Outstanding | 0.08% | 0.23% | |||
| Average Diluted Shares Outstanding | 0.08% | -6.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||